Wednesday, July 22, 2009

Depomed Provides License for Patents Covering Metformin Extended Release Technology to Merck & Co., Inc.

Jul 22, 2009 - Depomed, Inc. today announced that it has provided a license to certain patents directed to metformin extended release technology to Merck & Co., Inc. to be used in developing fixed dose combinations of sitagliptin and extended release metformin.

The details can be read here.

No comments: